They have been used in other applications, e.g. LDN-193189 in atherosclerosis research and (5Z)-7-Oxozeaenol in cancer studies; however, this was not to specifically modulate TGFβ signaling but to inhibit BMP and TAK1 signaling, respectively. This evidence concerns the gene MAP3K7 and atherosclerosis.